Surgical revascularization of renal artery after complicated or failed percutaneous transluminal renal angioplasty

Tc99m-dimercaptosuccinic acid renal uptake (DMSA uptake) was examined to assess the changes in split renal function following percutaneous transluminal renal angioplasty (PTRA) in 9 patients with a total of 12 renal artery stenoses and renovascular hypertension (RVH). The results were studied with respect to age, degree of renal artery stenosis, and renal vein renin ratio (RVRR) before PTRA. Although the degree of renal artery stenosis, systolic blood pressure, and peripheral blood plasma renin activity were improved 3 months after PTRA, neither the DMSA uptake of the affected kidneys nor that of the contralateral kidneys improved. Although restenosis occurred during the long follow-up period in one patient, DMSA uptake did not change in parallel with the degree of stenosis or RVRR. The degree of improvement in DMSA uptake, blood pressure, and plasma renin activity after PTRA in patients aged under 70 years was significantly higher than that in patients 70 years or older. Good improvement of renal function was attained in a 4-year-old boy, despite the fact that split renal function prior to PTRA was so poor that nephrectomy had been considered instead of PTRA. These results suggest that several factors before PTRA, such as DMSA uptake, degree of renal artery stenosis, and RVRR, are not absolutely predictive of results after PTRA, and that the effect of PTRA on blood pressure and renal function is greater in younger patients.

Download Full-text

Abstract P165: Incident and Associated Factors of Restenosis After Percutaneous Transluminal Renal Angioplasty in Renovascular Hypertensive Patients

Hypertension ◽

10.1161/hyp.66.suppl_1.p165 ◽

2015 ◽

Vol 66 (suppl_1) ◽

Author(s):

Yoshio Iwashima ◽

Tetsuya Fukuda ◽

Fumiki Yoshihara ◽

Hiroshi Kusunoki ◽

Masatsugu Kishida ◽

...

Keyword(s):

Renal Artery ◽

Associated Factors ◽

Antihypertensive Medication ◽

Treatment Success ◽

Peak Systolic Velocity ◽

Hypertensive Patients ◽

Renal Angioplasty ◽

Significant Difference ◽

Percutaneous Transluminal Renal Angioplasty ◽

Percutaneous Transluminal

Background: Percutaneous transluminal renal angioplasty (PTRA) is one of the standard treatments for renal artery stenosis (RAS). Restenosis after PTRA may influence disease prognosis, but little is unknown about the frequency or its associated factors. Methods: This study included 174 renovascular hypertensive patients (mean age= 59.5 years; 33.9% women) who underwent PTRA and were followed more than 12 months after PTRA. Data collection including blood pressure (BP), intensity of antihypertensive medication, and duplex ultrasonography (DUS) was performed before and 3, 6, and 12 months after PTRA. Cure of hypertension was defines as a BP below 140/90mmHg without antihypertensive medication. Diagnosis of restenosis was based on DUS, by applying a renal aortic ratio >3.5 in conjunction with a renal artery peak systolic velocity > 250cm/s. Results: At 12 months after PTRA, BP (156±25/82±15 to 133±16/75±13mmHg) as well as antihypertensive medications (2.5±1.2 to 2.1±1.3 types) decreased significantly (p<0.01, respectively), and the incident of restenosis was 34 (19.5%). Compared with patients without restenosis, baseline clinical characteristics in those with restenosis showed significantly younger (46.1±23.6 vs 62.8±16.3 years), higher prevalence of female (50.0 vs 30.0%), fibromuscular dysplasia (FMD) diagnosed by angiography (58.8 vs 23.6%), and balloon PTRA without stenting (44.1 vs 18.6%), and lower numbers of antiplatelet and/or anticoagulant agents administrated after PTRA (1.3±0.6 vs 1.7±0.6 types of drug) (p<0.05, respectively). Compared with atherosclerotic RAS patients (n=121), the rates of cured (25.9 vs 9.0%) and the cumulative incident rates of restenosis at 3 (20.8 vs 0 %), 6 (35.9 vs 6.6%), and 12 (37.7 vs 11.6%) months after PTRA were significantly higher in FMD (p<0.01, respectively). FMD without restenosis showed a significantly greater decrease in systolic BP than that with (159±21 to 131±17 vs 154±28 to 141±25 mmHg, p<0.05), whereas no significant difference was found in atherosclerotic RAS. Conclusions: Incident of restenosis after PTRA was higher in FMD than in atherosclerotic, and its incident pattern seemed to be different by causes. Especially for FMD, assessment of restenosis is important for treatment success.

Download Full-text